USP30 inhibitors promoting mitophagy act with comparable efficiency in the lung fibrosis model to the pirfenidone which is a therapy approved in IPF treatment (Adnot et al., 2019). This evidence concerns the gene USP30 and idiopathic pulmonary fibrosis.